|
1
|
Ferenci P, Fried M, Labrecque D, Bruix J,
Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA,
et al: Hepatocellular carcinoma (HCC): A global perspective. J Clin
Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li J, Wang K, Chen X, Meng H, Song M, Wang
Y, Xu X and Bai Y: Transcriptional activation of microRNA-34a by
NF-kappa B in human esophageal cancer cells. BMC Mol Biol.
13:42012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta P, Cairns MJ and Saksena NK:
Regulation of gene expression by microRNA in HCV infection and
HCV-mediated hepatocellular carcinoma. Virol J. 11:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Enguita-Germán M and Fortes P: Targeting
the insulin-like growth factor pathway in hepatocellular carcinoma.
World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhaskar PT and Hay N: The two TORCs and
Akt. Dev Cell. 12:487–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toker A and Yoeli-Lerner M: Akt signaling
and cancer: Surviving but not moving on. Cancer Res. 66:3963–3966.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brodbeck D, Hill MM and Hemmings BA: Two
splice variants of protein kinase B gamma have different regulatory
capacity depending on the presence or absence of the regulatory
phosphorylation site serine 472 in the carboxyl-terminal
hydrophobic domain. J Biol Chem. 276:29550–29558. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brodbeck D, Cron P and Hemmings BA: A
human protein kinase Bgamma with regulatory phosphorylation sites
in the activation loop and in the C-terminal hydrophobic domain. J
Biol Chem. 274:9133–9136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grottke A, Ewald F, Lange T, Nörz D,
Herzberger C, Bach J, Grabinski N, Gräser L, Höppner F, Nashan B,
et al: Downregulation of AKT3 increases migration and metastasis in
triple negative breast cancer cells by upregulating S100A4. PLoS
One. 11:e01463702016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun M, Wang G, Paciga JE, Feldman RI, Yuan
ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng
JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers
and its constitutive activation is required for oncogenic
transformation in NIH3T3 cells. Am J Pathol. 159:431–437. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee MY, Luciano AK, Ackah E,
Rodriguez-Vita J, Bancroft TA, Eichmann A, Simons M, Kyriakides TR,
Morales-Ruiz M and Sessa WC: Endothelial Akt1 mediates angiogenesis
by phosphorylating multiple angiogenic substrates. Proc Natl Acad
Sci U S A. 111:12865–12870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol
K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al: Growth
retardation and increased apoptosis in mice with homozygous
disruption of the Akt1 gene. Genes Dev. 15:2203–2208. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho H, Thorvaldsen JL, Chu Q, Feng F and
Birnbaum MJ: Akt1/PKBalpha is required for normal growth but
dispensable for maintenance of glucose homeostasis in mice. J Biol
Chem. 276:38349–38352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu N, Lao Y, Zhang Y and Gillespie DA:
Akt: A double-edged sword in cell proliferation and genome
stability. J Oncol. 2012:9517242012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Z, Xu Z, Disante G, Wright J, Wang M,
Li Y, Zhao Q, Ren T, Ju X, Gutman E, et al: miR-17/20 sensitization
of breast cancer cells to chemotherapy-induced apoptosis requires
Akt1. Oncotarget. 5:1083–1090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Green BD, Jabbour AM, Sandow JJ, Riffkin
CD, Masouras D, Daunt CP, Salmanidis M, Brumatti G, Hemmings BA,
Guthridge MA, et al: Akt1 is the principal Akt isoform regulating
apoptosis in limiting cytokine concentrations. Cell Death Differ.
20:1341–1349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ewald F, Nörz D, Grottke A, Bach J,
Herzberger C, Hofmann BT, Nashan B and Jücker M: Vertical targeting
of AKT and mTOR as well as dual targeting of AKT and MEK signaling
is synergistic in hepatocellular carcinoma. J Cancer. 6:1195–1205.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol
K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al: Growth
retardation and increased apoptosis in mice with homozygous
disruption of the akt1 gene. Genes Dev. 15:2203–2208. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee MS, Jeong MH, Lee HW, Han HJ, Ko A,
Hewitt SM, Kim JH, Chun KH, Chung JY, Lee C, et al: PI3K/AKT
activation induces PTEN ubiquitination and destabilization
accelerating tumourigenesis. Nat Commun. 6:77692015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He X, Saji M, Radhakrishnan D, Romigh T,
Ngeow J, Yu Q, Wang Y, Ringel MD and Eng C: PTEN lipid phosphatase
activity and proper subcellular localization are necessary and
sufficient for down-regulating AKT phosphorylation in the nucleus
in cowden syndrome. J Clin Endocrinol Metab. 97:E2179–E2187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Serra H, Chivite I, Angulo-Urarte A, Soler
A, Sutherland JD, Arruabarrena-Aristorena A, Ragab A, Lim R,
Malumbres M, Fruttiger M, et al: PTEN mediates Notch-dependent
stalk cell arrest in angiogenesis. Nat Commun. 6:79352015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jo HS, Kang KH, Joe CO and Kim JW: Pten
coordinates retinal neurogenesis by regulating Notch signaling.
EMBO J. 31:817–828. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vo K, Amarasinghe B, Washington K,
Gonzalez A, Berlin J and Dang TP: Targeting notch pathway enhances
rapamycin antitumor activity in pancreas cancers through PTEN
phosphorylation. Mol Cancer. 10:1382011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD and Yang SM: miR-149
represses metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chow AK, Ng L, Lam CS, Wong SK, Wan TM,
Cheng NS, Yau TC, Poon RT and Pang RW: The enhanced metastatic
potential of hepatocellular carcinoma (HCC) cells with sorafenib
resistance. PLoS One. 8:e786752013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Llovet JM, Fuster J and Bruix J: The
Barcelona approach: Diagnosis, staging, and treatment of
hepatocellular carcinoma. Liver Transpl. 10:S115–120. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bellacosa A, Testa JR, Staal SP and
Tsichlis PN: A retroviral oncogene, akt, encoding a
serine-threonine kinase containing an SH2-like region. Science.
254:274–277. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bellacosa A, Franke TF, Gonzalez-Portal
ME, Datta K, Taguchi T, Gardner J, Cheng JQ, Testa JR and Tsichlis
PN: Structure, expression and chromosomal mapping of c-akt:
Relationship to v-akt and its implications. Oncogene. 8:745–754.
1993.PubMed/NCBI
|
|
38
|
Yang ZZ, Tschopp O, Hemmings-Mieszczak M,
Feng J, Brodbeck D, Perentes E and Hemmings BA: Protein kinase B
alpha/Akt1 regulates placental development and fetal growth. J Biol
Chem. 278:32124–32131. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Skeen JE, Bhaskar PT, Chen CC, Chen WS,
Peng XD, Nogueira V, Hahn-Windgassen A, Kiyokawa H and Hay N: Akt
deficiency impairs normal cell proliferation and suppresses
oncogenesis in a p53-independent and mTORC1-dependent manner.
Cancer Cell. 10:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu YJ, Li HY, Qiu KJ, Li DC, Zhou JH, Hu
YH and Zhang FM: Downregulation of Notch1 inhibits the invasion of
human hepatocellular carcinoma HepG2 and MHCC97H cells through the
regulation of PTEN and FAK. Int J Mol Med. 34:1081–1086. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X,
Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The
AKT1/NF-kappaB/Notch1/PTEN axis has an important role in
chemoresistance of gastric cancer cells. Cell Death Dis.
4:e8472013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hales EC, Orr SM, Gedman Larson A, Taub JW
and Matherly LH: Notch1 Receptor Regulates AKT protein activation
loop (Thr308) dephosphorylation through modulation of the PP2A
Phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell
acute lymphoblastic leukemia cells. J Biol Chem. 288:22836–22848.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Wang WL, Zhang Y, Guo SP, Zhang J
and Li QL: Epigenetic and genetic alterations of PTEN in
hepatocellular carcinoma. Hepatol Res. 37:389–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chow LM and Baker SJ: PTEN function in
normal and neoplastic growth. Cancer Lett. 241:184–196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu TH, Huang CC, Lin PR, Chang HW, Ger LP,
Lin YW, Changchien CS, Lee CM and Tai MH: Expression and prognostic
role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular
carcinoma. Cancer. 97:1929–1940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dong-Dong L, Xi-Ran Z and Xiang-Rong C:
Expression and significance of new tumor suppressor gene PTEN in
primary liver cancer. J Cell Mol Med. 7:67–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Palomero T, Sulis ML, Cortina M, Real PJ,
Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, et
al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition
in T-cell leukemia. Nat Med. 13:1203–1210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Miele L, Miao H and Nickoloff BJ: NOTCH
signaling as a novel cancer therapeutic target. Curr Cancer Drug
Targets. 6:313–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
